Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
about
Phosphate binders for preventing and treating bone disease in chronic kidney disease patientsHyperphosphatemia Management in Patients with Chronic Kidney DiseaseManagement of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guidelineLanthanum carbonate: safety data after 10 yearsHypophosphatemic effect of niacin in patients without renal failure: a randomized trial.Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label studyComparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patientsLanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.Pharmacology of the phosphate binder, lanthanum carbonateEfficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic reviewManagement of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate.Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.Osteo-renal regulation of systemic phosphate metabolism.Lanthanum, constipation, bafflying X-rays and a perforated colonic diverticulumA new paradigm for the treatment of secondary hyperparathyroidism.Emerging drugs for renal failure.Hyperphosphatemia in renal failure.Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.Accumulation of metals and minerals from phosphate binders.Sevelamer carbonate experience in Indian end stage renal disease patients.Phosphate binders: new products and challenges.The safety of phosphate binders.Management of hyperphosphatemia.Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs.Doxercalciferol treatment of secondary hyperparathyroidism.Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysisHigher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter studySwitching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.Emerging drugs for hyperphosphatemia.New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease.Syntheses, Characterization, Thermal, and Antimicrobial Studies of Lanthanum(III) Tolyl/BenzyldithiocarbonatesEffects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.Advances in pharmacotherapy for secondary hyperparathyroidism.Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.Lanthanum-Induced Gastrointestinal Histiocytosis.The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients.Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate.
P2860
Q24234036-7630C6DB-ABC5-48AC-BF56-B3E88D0049B8Q26743842-9E63823C-3D93-498D-A24E-DE40FC542E41Q26866391-5FA67DB0-9740-49C4-9B7A-7D370017C43AQ28079982-3A07AF39-AE07-4CA5-92F8-0E3078C7E094Q33770086-A0E2EEF5-396D-43A6-BC3F-5A359A2BEEF0Q34036349-F4E99D0F-FEC9-418E-9D14-91FEA6CEF027Q34497220-AF28878F-4D9F-4FCA-B5F9-884108421F18Q34573734-7556403C-FD29-4F9A-B8AB-9DA3DD359FA9Q34854318-9A7FD335-B7BE-4A06-A1F4-6DB360ED6EDAQ35019709-9779022E-4A6F-45FB-BC14-937BADB07A81Q35026657-1676D193-CBBD-4091-978B-A816CCE329C4Q35030613-4592DADC-8354-4556-BFD0-AF99DDB661E1Q35059741-FB6B328C-38F4-47C1-9551-E3C83CFAC2BDQ35366628-D481D7E6-FE67-434E-9EF7-943DA61A89DAQ35573634-EDC17182-73B7-418C-804B-910EA969E79CQ35602657-235BB749-D065-48EF-B563-0D2D849420B5Q35997644-FE095456-1A39-4385-BF45-6C0102EAFF73Q36082068-B3BEE760-4B3F-4E35-9F59-3F2F0052270FQ36098773-D0A8C539-273E-4C48-8A3B-7F613066AACCQ36283544-3C52A3DE-3EE7-4A75-9215-DCCD78A6CA0FQ36522027-1CD57743-AFB9-4858-910D-C1640E29AA26Q36565049-AE8DC4BB-6E73-4991-877C-4076EF64E5FFQ36609857-AE3A9E04-87AE-46D2-814F-660A5F53DAA5Q36632228-8F5D0410-33E6-480B-992E-926D36283DE4Q36633869-5D376E95-49D4-4D11-9B29-D6FFDD15BEB4Q36831509-4851C344-82A5-45F9-8FCD-EEEBA0FA02B9Q36843430-12AE2F70-FC7B-4EB6-96C7-0176A0A81858Q36938843-CD6E9A0D-A827-4739-BD2B-726022831CB1Q36944004-E2D0C1F7-AD7A-4F41-A028-8AE4F6D51FABQ37111857-A22328C3-CA66-4616-B7B3-A13DBB8F7C09Q37368351-529211F3-449D-4F01-9073-0FB334E317FDQ37725517-6F3C8EDD-FD56-429B-96D7-46C71CA25C8EQ38132834-4FAECCF5-32FC-4D3C-B805-168382297D25Q38544533-608EB260-2413-47E5-8150-E6F8CBB64962Q38824573-E3330678-B713-435C-A232-69A0228152A9Q39430387-EE646280-92AD-4CDD-AB40-EB7A59341253Q40148090-78E4B24D-F734-4368-B0CC-EA4ABA10E671Q40930877-3EDCE4C7-8E8D-409D-8866-135AB9F6DCD4Q41913376-90EDC5D1-5AD2-4D89-8DAE-D27109A006BCQ42260120-4E57B976-1189-4675-B138-BC6C44237620
P2860
Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Randomized, double-blind, plac ...... reatment of hyperphosphatemia.
@en
Randomized, double-blind, plac ...... reatment of hyperphosphatemia.
@nl
type
label
Randomized, double-blind, plac ...... reatment of hyperphosphatemia.
@en
Randomized, double-blind, plac ...... reatment of hyperphosphatemia.
@nl
prefLabel
Randomized, double-blind, plac ...... reatment of hyperphosphatemia.
@en
Randomized, double-blind, plac ...... reatment of hyperphosphatemia.
@nl
P2093
P1476
Randomized, double-blind, plac ...... reatment of hyperphosphatemia.
@en
P2093
LAM-302 Study Group
Melanie S Joy
William F Finn
P304
P356
10.1016/S0272-6386(03)00554-7
P577
2003-07-01T00:00:00Z